United Therapeutics (UTHR) announced that ten posters and presentations across its commercial and development portfolio will be presented at ...

Drug developers will now have enhanced abilities to rapidly prototype, test, iterate, and scale up their mRNA therapeutics.

Biotech innovator Denali Therapeutics opened a new manufacturing hub as it develops new therapies for conditions like Hunter ...

Key to 400-employee Denali's submission is the FDA allowing measurement of a type of GAG, called heparan sulfate, in ...

We recently published a list of 7 Most Profitable Biotech Stocks To Buy Right Now. In this article, we are going to take a ...

Revenue reached $74.67M, exceeding guidance and demonstrating continued strong sales growth and execution ---- Net Income ...

The decision came after the discovery of a problem with the methodology used in these data sets. The issue impacts data from the year 2008 onward, but the most significant effect on annual producer ...

Onward Robotics Showcases Innovative Meet Me® Solution for Automated Order Fulfillment With Live Demonstrations at ProMat 2025 "We're on a mission to revolutionize fulfillment, helping ...

Check Out Our Latest Analysis on United Therapeutics United Therapeutics Stock Down 1.6 % UTHR stock opened at $313.60 on Wednesday. United Therapeutics has a 52-week low of $221.53 and a 52-week ...

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.

Nurix Therapeutics, Inc. has a 1-year low of $11.90 and a 1-year high of $29.56. The company has a market cap of $1.05 billion, a price-to-earnings ratio of -4.81 and a beta of 2.18.